DR.U.G.@DrUddiptyaGoswami
@uddiptyagoswami.bsky.social
Medical Oncology & Hematology
Apollo Hospitals Chennai
ESMO 1 year mentee 2024
ROCHE LEAP winner
Precision Oncology
Accessible & Affordable Care
Early Supportive & Palliative Care
Cancer Care giver in the family- one who knows the grass on the other side!
Apollo Hospitals Chennai
ESMO 1 year mentee 2024
ROCHE LEAP winner
Precision Oncology
Accessible & Affordable Care
Early Supportive & Palliative Care
Cancer Care giver in the family- one who knows the grass on the other side!
Reposted by DR.U.G.@DrUddiptyaGoswami
Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓
💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives
Grateful to work with a global amazing team 🙏
Link to the Review:👇
doi.org/10.1016/j.ctrv…
💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives
Grateful to work with a global amazing team 🙏
Link to the Review:👇
doi.org/10.1016/j.ctrv…
February 16, 2025 at 6:53 PM
Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓
💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives
Grateful to work with a global amazing team 🙏
Link to the Review:👇
doi.org/10.1016/j.ctrv…
💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives
Grateful to work with a global amazing team 🙏
Link to the Review:👇
doi.org/10.1016/j.ctrv…
Reposted by DR.U.G.@DrUddiptyaGoswami
This year's edition of our annual Notable Articles collection, selected by NEJM editors, showcases the most significant contributions to clinical medicine and patient care. Download the collection: nej.md/4gHiO1V
#MedSky
#MedSky
December 24, 2024 at 8:07 PM
This year's edition of our annual Notable Articles collection, selected by NEJM editors, showcases the most significant contributions to clinical medicine and patient care. Download the collection: nej.md/4gHiO1V
#MedSky
#MedSky
Reposted by DR.U.G.@DrUddiptyaGoswami
2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA:
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
December 24, 2024 at 3:07 AM
2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA:
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
Reposted by DR.U.G.@DrUddiptyaGoswami
Donate blood and stem cells🙏
It doesnt hurt and you save a life.
Register now @dkms-de.bsky.social or others🩸
It doesnt hurt and you save a life.
Register now @dkms-de.bsky.social or others🩸
November 23, 2024 at 5:46 AM
Donate blood and stem cells🙏
It doesnt hurt and you save a life.
Register now @dkms-de.bsky.social or others🩸
It doesnt hurt and you save a life.
Register now @dkms-de.bsky.social or others🩸
Reposted by DR.U.G.@DrUddiptyaGoswami
ACOG recommends starting mammography at age 40 for those at average breast cancer risk, due to a 2% annual increase in cases among women aged 40-49 from 2015 to 2019. This update aligns with other major health organizations, advising continued screening every 1 to 2 years.
https://buff.ly/3UVMgJ0
https://buff.ly/3UVMgJ0
November 16, 2024 at 12:48 PM
ACOG recommends starting mammography at age 40 for those at average breast cancer risk, due to a 2% annual increase in cases among women aged 40-49 from 2015 to 2019. This update aligns with other major health organizations, advising continued screening every 1 to 2 years.
https://buff.ly/3UVMgJ0
https://buff.ly/3UVMgJ0
Reposted by DR.U.G.@DrUddiptyaGoswami
Recommend this excellent review from @BCJoyceO and co
“Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach” #MedTwitter #bcsm ascopubs.org/doi/abs/10.1...
“Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach” #MedTwitter #bcsm ascopubs.org/doi/abs/10.1...
Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach | JCO Oncology Practice
Circulating tumor DNA (ctDNA) refers to DNA fragments released from cancer cells into
the bloodstream. Clinical utility of ctDNA in breast cancer has been explored in both
metastatic breast cancer (MB...
ascopubs.org
November 16, 2024 at 11:19 AM
Recommend this excellent review from @BCJoyceO and co
“Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach” #MedTwitter #bcsm ascopubs.org/doi/abs/10.1...
“Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach” #MedTwitter #bcsm ascopubs.org/doi/abs/10.1...